The discovery of activated KRAS oncogenes in human cancer cell lines in 1982 (9, 10), and their establishment as a sufficient (11) and necessary driver of PDAC growth (12–14), supported the potential significance of KRAS-targeted therapies for PDAC treatment. Here, KRAS is linked to cancer.